Reuters logo
BRIEF-Biomerica extends license agreement with Celtis Pharm
2017年11月7日 / 下午1点39分 / 13 天前

BRIEF-Biomerica extends license agreement with Celtis Pharm

Nov 7 (Reuters) - Biomerica Inc:

* Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019

* Biomerica Inc - has extended its exclusive license agreement with Celtis Pharm Co. Ltd of South Korea​

* Biomerica - ‍term of exclusivity agreement is five years with an additional two years for telcon to receive Korean FDA clearance​

* Biomerica - agreement may be cancelled if co has not obtained final clearance for sale of products in U.S. from FDA on or before December 31, 2019​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below